Leadership in Antimicrobial Innovation

At Natureza Research, our team brings together decades of experience in infectious disease, pharmaceutical development, and international collaboration. Each member contributes to Natureza’s mission to develop scientifically validated, resistance-proof antimicrobial agents.

LYNN JAMES-MEYER, Founder/CEO, BA

Founder, Product Developer and CEO of BioSafe Technologies, Inc. (women owned) in 2000
Founder and CEO of Natureza Research, Inc. (women owned) in 2009 to expand its antimicrobial R&D program
Majority Owner GML Industries, LLC since 1995
2016 Global Exporter of the Year Award from the Global Chamber, TX
2017 Gold International Stevie Award for Women in Business Female Entrepreneur of the Year
2017 Gold International Stevie Award for Maverick of the Year
2017 Silver International Stevie Award for Lifetime Achievements in Business

Worked with Natureza for over 12 years and is its antimicrobial projects manager.
Senior Lecturer in Infectious Disease at the University of Bristol with 20 years of experience in the development of anti-infective interventions in human and animal disease.
Received his undergraduate degree in Biology and PhD in Microbiology at the University of Exeter, UK.
He is an academic and co founder of a probiotics manufacturer, Ferryx Ltd.
His association with Natureza came about after observing a colleague working with an antiparasitic formulation and seeing that this appeared to have both anti-inflammatory and antimicrobial activity. He has worked to identify the molecules responsible for these, to modify and optimise them and to formulate them into Natureza’s current range of patented antimicrobials.
Authored over 100 scientific papers, obtained >$10M in grant funding.
Contributed to a number of patents resulting from his academic work with industry and his work with Natureza.

Chief Scientific Advisor
MA, Biochemistry,Cambridge
PhD Insect Biochemistry
ScD based on Selected Research Publications
8 Years Supported by Wellcome Trust
9 years ICI Pharmaceuticals
7 years University of Massachusetts
6 Years Head of Parasitology Department of Central Veterinary Laboratory
Senior Research Scientist University of Bristol
Author or co-author of 300+ Scientific Publications

16 years as Director of Finance and International Development for Biosafe Technologies, Inc.
9 years as Managing Director of Natureza Research.
2 years CEO Italiana Prodotti Minerali (Genoa -Italy)
24 years represented multinational corporations on international trade issues (primarily Washington DC).

Natureza Patents New Antibiotic Agents

Our active ingredients have activity against many of the multi-drug resistant pathogens resistant to traditional antibiotics.
These unique compounds effectively target harmful bacteria and fungi against dangerous infections and have shown no resistance over long term testing.

Natureza’s findings inform new perspectives in antibiotic development that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years, providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much-needed antibiotics.

This work is protected by US and foreign patents and patents pending.